- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Hong Kong Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
84
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
84 companies
Genor Biopharma Holdings
Market Cap: HK$1.4b
A biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally.
6998
HK$2.64
7D
-1.5%
1Y
107.9%
Ocumension Therapeutics
Market Cap: HK$6.1b
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.
1477
HK$7.53
7D
-2.2%
1Y
11.7%
CARsgen Therapeutics Holdings
Market Cap: HK$11.1b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States.
2171
HK$20.15
7D
-11.2%
1Y
183.8%
Sino Biopharmaceutical
Market Cap: HK$79.1b
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
1177
HK$4.42
7D
5.0%
1Y
57.9%
China Traditional Chinese Medicine Holdings
Market Cap: HK$11.4b
China Traditional Chinese Medicine Holdings Co.
570
HK$2.26
7D
5.1%
1Y
-46.6%
Zhaoke Ophthalmology
Market Cap: HK$1.5b
An ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong.
6622
HK$2.73
7D
17.2%
1Y
80.8%
JBM (Healthcare)
Market Cap: HK$2.1b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.54
7D
-1.9%
1Y
170.2%
Consun Pharmaceutical Group
Market Cap: HK$8.8b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$10.60
7D
6.2%
1Y
61.8%
3SBio
Market Cap: HK$46.6b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$19.76
7D
-1.1%
1Y
217.2%
Brii Biosciences
Market Cap: HK$1.4b
Focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.
2137
HK$1.95
7D
9.6%
1Y
65.3%
JW (Cayman) Therapeutics
Market Cap: HK$831.0m
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of cellular immunotherapy products in the People’s Republic of China.
2126
HK$2.05
7D
19.9%
1Y
-5.5%
Essex Bio-Technology
Market Cap: HK$3.0b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$5.29
7D
14.8%
1Y
104.2%
Modern Chinese Medicine Group
Market Cap: HK$228.0m
An investment holding company, engages in the production and sale of proprietary Chinese medicines for elderlies and middle aged in the People's Republic of China.
1643
HK$0.38
7D
5.6%
1Y
0%
VISEN Pharmaceuticals
Market Cap: HK$5.2b
An investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan.
2561
HK$45.50
7D
-3.3%
1Y
n/a
Wai Yuen Tong Medicine Holdings
Market Cap: HK$399.4m
An investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong.
897
HK$0.35
7D
-1.4%
1Y
58.5%
WuXi Biologics (Cayman)
Market Cap: HK$104.7b
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.
2269
HK$25.75
7D
7.1%
1Y
129.9%
Jacobio Pharmaceuticals Group
Market Cap: HK$4.2b
An investment holding company, engages in the in-house discovery and development of oncology therapies.
1167
HK$5.37
7D
11.6%
1Y
219.6%
Antengene
Market Cap: HK$2.6b
A biopharmaceutical company, develops novel oncology therapies in Greater China and internationally.
6996
HK$3.88
7D
-0.3%
1Y
300.0%
Ascletis Pharma
Market Cap: HK$6.8b
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
1672
HK$7.10
7D
7.3%
1Y
482.0%
Abbisko Cayman
Market Cap: HK$5.6b
An investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China.
2256
HK$8.93
7D
1.8%
1Y
174.8%
Kontafarma China Holdings
Market Cap: HK$178.8m
An investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediate in Mainland China, Singapore, Taiwan, and internationally.
1312
HK$0.032
7D
3.2%
1Y
-3.0%
China Health Group
Market Cap: HK$160.3m
An investment holding company, provides research and development services of drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China.
8225
HK$0.16
7D
-3.6%
1Y
43.8%
China Shineway Pharmaceutical Group
Market Cap: HK$5.8b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People’s Republic of China and Hong Kong.
2877
HK$7.66
7D
2.1%
1Y
-9.7%
Jacobson Pharma
Market Cap: HK$2.6b
Through its subsidiaries, develops, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally.
2633
HK$1.30
7D
0%
1Y
120.3%
United Laboratories International Holdings
Market Cap: HK$25.4b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$13.96
7D
7.1%
1Y
52.6%
Simcere Pharmaceutical Group
Market Cap: HK$30.2b
Engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
2096
HK$12.20
7D
18.0%
1Y
113.7%
Dawnrays Pharmaceutical (Holdings)
Market Cap: HK$1.8b
An investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally.
2348
HK$1.19
7D
0%
1Y
2.6%
China Medical System Holdings
Market Cap: HK$25.6b
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
867
HK$10.60
7D
16.9%
1Y
52.7%
Pak Fah Yeow International
Market Cap: HK$747.9m
An investment holding company, engages in manufacturing, marketing, and distributing healthcare products under the Hoe Hin brand name in Hong Kong, Macau, the People’s Republic of China, Southeast Asia, North America, the United Kingdom, and internationally.
239
HK$2.40
7D
-0.8%
1Y
-4.0%
Lee's Pharmaceutical Holdings
Market Cap: HK$877.4m
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China.
950
HK$1.49
7D
2.8%
1Y
20.2%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$68.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$307.00
7D
-6.1%
1Y
89.4%
Qyuns Therapeutics
Market Cap: HK$2.5b
A clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China.
2509
HK$11.32
7D
-0.4%
1Y
-60.9%
HBM Holdings
Market Cap: HK$7.0b
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel antibody therapeutics in immunology and oncology disease areas.
2142
HK$8.74
7D
-4.5%
1Y
498.6%
TOT BIOPHARM International
Market Cap: HK$1.4b
An investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally.
1875
HK$1.84
7D
0.5%
1Y
-12.4%
Shanghai Junshi Biosciences
Market Cap: HK$32.1b
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China.
1877
HK$20.90
7D
23.1%
1Y
82.1%
Jilin Province Huinan Changlong Bio-pharmacy
Market Cap: HK$1.2b
Manufactures and distributes Chinese medicines and pharmaceutical products in the People’s Republic of China.
8049
HK$2.12
7D
-4.1%
1Y
37.7%